Mark Godsy, CEO and co-founder and Dr. Alan Shackelford, co-founder of Shackelford Pharmaceuticals, sat down to discuss using real-world data to guide cannabinoid-based drug development at the Benzinga Capital Cannabis Conference in Chicago.

Shackelford Pharma is a clinical-stage biopharmaceutical company developing medicines for neurological diseases with significant unmet patient needs. Its first drug candidate …

Full story available on Benzinga.com